Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Cancer
Roche’s Rozlytrek Wins NMPA Approval for ROS1+ NSCLC Treatment
Swiss pharmaceutical giant Roche’s China unit announced that it has received market approval from the...
EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs
US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...
E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products
E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed...
Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...
InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma
InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...
BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...
Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer
Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...
HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study
Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval
Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...
Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...
Hywin Holdings to Acquire Life Infinity for Health Management Expansion
China-based wealth management firm Hywin Holdings is set to move into the health management business...
HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...
Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma
Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...
ProfoundBio Receives FDA Approval for PRO1184, Appoints New CMO
China-based macromolecular targeted therapy developer ProfoundBio (Suzhou) Co., Ltd announced that it has received clinical...
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...
ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas
China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources...
Aosaikang’s ASKG315 Receives Ethics Approval for Phase I Cancer Trial in Australia
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced it has received ethical approval from Australia’s...